explore -WSS

explore

author：explore 2025-09-28 23:31:35 - browse：575

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： FDA approves potent Eli Lilly obesity drug, Zepbound

explore

hotspot

WSS

Will General Catalyst be the first of many hospital takeovers?

Chronically ill young patients struggle to find fertility info

3 trends to watch in health tech's hiring outlook for 2024

White House calls on federal agencies to crack down on AI abuses

Diversify hospital leadership teams to protect BIPOC patient health

The Sacklers, horror, and ‘The Fall of the House of Usher’

focus

explore

knowledge

New air purifier tech could be key to improving indoor air quality

Free speech concerns arise in wake of journal editor Eisen's firing

How one medical school became remarkably diverse

Medicare will require more price transparency from hospitals

Medicare proposal to cover medical devices draws a mixed reaction

Federal weight loss drug coverage is 30 years out of date

Guidelines to prevent youth baseball injuries need more muscle

Will General Catalyst be the first of many hospital takeovers?

Supreme Court strikes down use of affirmative action

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

focus

Medicare will require more price transparency from hospitals

Biotech incubator Curie.Bio graduates its first startup

STAT Executive Editor Rick Berke on STAT's 8th birthday

Abortion clinic in Cancun will cater to Americans

Abortion clinic in Cancun will cater to Americans

U.K. sequencing study surfaces new findings about tumor DNA

explore

focus

hotspot

knowledge